Spots Global Cancer Trial Database for Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Official Title: A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Study ID: NCT00315757
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Scripps Clinic Medical Group, Inc., La Jolla, California, United States
Cancer and Blood Disorders Center, Lecanto, Florida, United States
University of Chicago, Chicago, Illinois, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Institute of Medical & Veterinary Science, Adelaide, South Australia, Australia
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Clinical Haematology & BMT, Alfred Hospital, Melbourne, Victoria, Australia
Tom Baker Cancer Center, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
Ottawa Health Research Institute - General Campus, Ottawa, Ontario, Canada
Notre Dame Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
Bharath Hospital & Institute of Oncology, Mysore, Karnataka, India
Bangalore Institute of Oncology, Bangalore, , India
All India Institute of Medical Sciences, New Delhi, , India
Rajiv Gandhi Cancer Institute & Research Center, New Delhi, , India
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
